HTFL

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 9

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By U.S. Venture Partners X, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 330,078 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 8

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By U.S. Venture Partners X, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 220,052 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 7

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By USVP X Affiliates, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 7,040 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 6

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By USVP X Affiliates, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 10,560 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 5

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By U.S. Venture Partners X, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 330,078 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 4

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By U.S. Venture Partners X, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 220,052 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · nonDerivative · entry 3

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,447

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · nonDerivative · entry 2

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By USVP X Affiliates, L.P.

Disclosed balance after: 98,303

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F4 · price: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By U.S. Venture Partners X, L.P.

Disclosed balance after: 3,072,759

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F4 · price: Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F6 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039737 · wk-form4_1754960486.xml · derivative · entry 5

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,704 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · shares: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.exercise_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.expiration_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039737 · wk-form4_1754960486.xml · derivative · entry 4

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,160 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · shares: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.exercise_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.expiration_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039737 · wk-form4_1754960486.xml · derivative · entry 3

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,442 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039737 · wk-form4_1754960486.xml · nonDerivative · entry 1

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039732 · wk-form4_1754960452.xml · derivative · entry 5

Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,578 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of Heartflow's common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.exercise_date: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of Heartflow's common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.expiration_date: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of Heartflow's common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039732 · wk-form4_1754960452.xml · nonDerivative · entry 2

Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,196

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of Heartflow's common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039731 · wk-form4_1754960446.xml · derivative · entry 3

BARABE TIMOTHY C · CIK 0001237409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 131,578 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039731 · wk-form4_1754960446.xml · nonDerivative · entry 1

BARABE TIMOTHY C · CIK 0001237409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · derivative · entry 11

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 96,068 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · shares: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F6 · derivative.exercise_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F6 · derivative.expiration_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · derivative · entry 10

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 452,528 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · shares: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · derivative.exercise_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · derivative.expiration_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · derivative · entry 9

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,337,337 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · shares: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · derivative.exercise_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · derivative.expiration_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · derivative · entry 8

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,099,378 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F4 · shares: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F4 · price: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F4 · derivative.exercise_date: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F4 · derivative.expiration_date: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · derivative · entry 7

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 208,604 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · derivative · entry 6

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,630,231 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · derivative · entry 5

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,248,939 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · derivative · entry 4

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 624,471 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · shares: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · nonDerivative · entry 3

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 4,615,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F4 · price: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F5 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F6 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · nonDerivative · entry 2

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund, L.P.

Disclosed balance after: 1,248,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001628280-25-039729 · wk-form4_1754960433.xml · nonDerivative · entry 1

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund II, L.P.

Disclosed balance after: 833,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F2 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

F3 · ownership.nature: Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000950170-25-107981 · ownership.xml · derivative · entry 4

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences III General Partner, LLC · CIK 0001952106 · 10% owner

Bain Capital Life Sciences Fund III, L.P. · CIK 0001875273 · 10% owner

BCLS Fund III Investments GP, LLC · CIK 0001952080 · 10% owner

BCLS Fund III Investments, LP · CIK 0001952107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 433,924 shares

Expires 2029-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The outstanding principal amount of the Subordinated Convertible Promissory note automatically converted into shares of the Issuer's Common Stock upon consummation of the Issuer's initial public offering at a conversion price of 80% of the price per share in the Issuer's initial public offering.

F3 · ownership.nature: Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").

F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0000950170-25-107981 · ownership.xml · derivative · entry 3

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences III General Partner, LLC · CIK 0001952106 · 10% owner

Bain Capital Life Sciences Fund III, L.P. · CIK 0001875273 · 10% owner

BCLS Fund III Investments GP, LLC · CIK 0001952080 · 10% owner

BCLS Fund III Investments, LP · CIK 0001952107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 12,014,234 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 0.342466:1 basis immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 0.342466:1 basis immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 0.342466:1 basis immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date.

F3 · ownership.nature: Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").

F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0000950170-25-107981 · ownership.xml · nonDerivative · entry 2

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences III General Partner, LLC · CIK 0001952106 · 10% owner

Bain Capital Life Sciences Fund III, L.P. · CIK 0001875273 · 10% owner

BCLS Fund III Investments GP, LLC · CIK 0001952080 · 10% owner

BCLS Fund III Investments, LP · CIK 0001952107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 12,448,158

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · ownership.nature: Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").

F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0000950170-25-107981 · ownership.xml · nonDerivative · entry 1

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences III General Partner, LLC · CIK 0001952106 · 10% owner

Bain Capital Life Sciences Fund III, L.P. · CIK 0001875273 · 10% owner

BCLS Fund III Investments GP, LLC · CIK 0001952080 · 10% owner

BCLS Fund III Investments, LP · CIK 0001952107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 12,014,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 0.342466:1 basis immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date.

F3 · ownership.nature: Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").

F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · derivative · entry 11

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 96,068 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · shares: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II herein on an as-converted basis.

F7 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II herein on an as-converted basis.

F7 · derivative.exercise_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II herein on an as-converted basis.

F7 · derivative.expiration_date: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II herein on an as-converted basis.

F8 · ownership.nature: HCPCIV 1, LLC ("HCPCIV") is a private investment limited liability company which is the direct beneficial owner of the securities reported herein. The shares held by HCPCIV may be determined to be beneficially owned by HCP2LP, its managing member, and by HCPGP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPCOV except to the extent of any pecuniary interest therein.

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · derivative · entry 10

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 452,528 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · shares: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · derivative.exercise_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · derivative.expiration_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F8 · ownership.nature: HCPCIV 1, LLC ("HCPCIV") is a private investment limited liability company which is the direct beneficial owner of the securities reported herein. The shares held by HCPCIV may be determined to be beneficially owned by HCP2LP, its managing member, and by HCPGP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPCOV except to the extent of any pecuniary interest therein.

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · derivative · entry 9

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,337,337 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · shares: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · derivative.exercise_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · derivative.expiration_date: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F8 · ownership.nature: HCPCIV 1, LLC ("HCPCIV") is a private investment limited liability company which is the direct beneficial owner of the securities reported herein. The shares held by HCPCIV may be determined to be beneficially owned by HCP2LP, its managing member, and by HCPGP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPCOV except to the extent of any pecuniary interest therein.

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · derivative · entry 8

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,099,378 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F5 · shares: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F5 · price: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F5 · derivative.exercise_date: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F5 · derivative.expiration_date: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F8 · ownership.nature: HCPCIV 1, LLC ("HCPCIV") is a private investment limited liability company which is the direct beneficial owner of the securities reported herein. The shares held by HCPCIV may be determined to be beneficially owned by HCP2LP, its managing member, and by HCPGP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPCOV except to the extent of any pecuniary interest therein.

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · derivative · entry 7

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 208,604 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F4 · ownership.nature: HealthCor Partners Fund II, L.P. ("HCPII Fund") is a private investment partnership which is the direct beneficial owner of the securities reported herein. The shares held by HCPII Fund may be deemed to be beneficially owned by HealthCor Partners II L.P. ("HCP2LP"), its general partner, and by HCPGP, the general partner of HCP2LP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPII Fund except to the extent of any pecuniary interest therein

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · derivative · entry 6

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,630,231 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · shares: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · derivative.exercise_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · derivative.expiration_date: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F8 · ownership.nature: HCPCIV 1, LLC ("HCPCIV") is a private investment limited liability company which is the direct beneficial owner of the securities reported herein. The shares held by HCPCIV may be determined to be beneficially owned by HCP2LP, its managing member, and by HCPGP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPCOV except to the extent of any pecuniary interest therein.

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · derivative · entry 5

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 624,471 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F1 · shares: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F1 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F4 · ownership.nature: HealthCor Partners Fund II, L.P. ("HCPII Fund") is a private investment partnership which is the direct beneficial owner of the securities reported herein. The shares held by HCPII Fund may be deemed to be beneficially owned by HealthCor Partners II L.P. ("HCP2LP"), its general partner, and by HCPGP, the general partner of HCP2LP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPII Fund except to the extent of any pecuniary interest therein

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · derivative · entry 4

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,248,939 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F1 · shares: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F1 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F1 · derivative.exercise_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F1 · derivative.expiration_date: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F2 · ownership.nature: HealthCor Partners Fund, L.P. ("HCP Fund") is a private investment partnership which is the direct beneficial owner of the securities reported herein. The shares held by HCP Fund may be deemed to be beneficially owned by HealthCor Partners L.P. ("HCPLP"), its general partner, and by HealthCor Partners GP, LLC ("HCPGP"), the general partner of HCPLP. Each of HCPLP and HCPGP hereby disclaims any beneficial ownership of shares held by HCP Fund except to the extent of any pecuniary interest therein

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · nonDerivative · entry 3

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV 1, LLC

Disclosed balance after: 4,615,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F5 · price: Each share of Series E preferred stock automatically converted into approximately 0.6951 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F6 · price: Each share of Series F preferred stock and Series F-1 preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F7 · price: Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II herein on an as-converted basis.

F8 · ownership.nature: HCPCIV 1, LLC ("HCPCIV") is a private investment limited liability company which is the direct beneficial owner of the securities reported herein. The shares held by HCPCIV may be determined to be beneficially owned by HCP2LP, its managing member, and by HCPGP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPCOV except to the extent of any pecuniary interest therein.

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · nonDerivative · entry 2

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund II, L.P.

Disclosed balance after: 833,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F3 · price: Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F4 · ownership.nature: HealthCor Partners Fund II, L.P. ("HCPII Fund") is a private investment partnership which is the direct beneficial owner of the securities reported herein. The shares held by HCPII Fund may be deemed to be beneficially owned by HealthCor Partners II L.P. ("HCP2LP"), its general partner, and by HCPGP, the general partner of HCP2LP. Each of HCP2LP and HCPGP hereby disclaims any beneficial ownership of shares held by HCPII Fund except to the extent of any pecuniary interest therein

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001062993-25-014851 · form4.xml · nonDerivative · entry 1

HealthCor Partners Management LP · CIK 0001519462 · 10% owner

HealthCor Partners GP, LLC · CIK 0001519460 · 10% owner

HealthCor Partners Fund LP · CIK 0001408660 · 10% owner

HealthCor Partners LP · CIK 0001519456 · 10% owner

HealthCor Partners Fund II, L.P. · CIK 0001538581 · 10% owner

HealthCor Partners II, L.P. · CIK 0001643094 · 10% owner

HCPCIV 1, LLC · CIK 0002083103 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By HealthCor Partners Fund, L.P.

Disclosed balance after: 1,248,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported on Table II herein on an as-converted basis.

F2 · ownership.nature: HealthCor Partners Fund, L.P. ("HCP Fund") is a private investment partnership which is the direct beneficial owner of the securities reported herein. The shares held by HCP Fund may be deemed to be beneficially owned by HealthCor Partners L.P. ("HCPLP"), its general partner, and by HealthCor Partners GP, LLC ("HCPGP"), the general partner of HCPLP. Each of HCPLP and HCPGP hereby disclaims any beneficial ownership of shares held by HCP Fund except to the extent of any pecuniary interest therein

F9 · ownership.nature: HealthCor Partners Management, L.P. is the investment manager for each of HCP Fund, HCPH Fund, and HCPCIV and has voting and investment discretion with respect to such entities' securities reported herein. HealthCor Partners Management, L.P. hereby disclaims any beneficial ownership of shares held by HCP Fund, HCPH Fund, and HCPCIV except to the extent of any pecuiary interest therein.

SEC source: 0001628280-25-039734 · wk-form4_1754960465.xml · derivative · entry 3

Verghese Vikram · CIK 0002079946 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,629

Underlying: Common Stock · 110,629 shares

Expires 2035-08-07

F3 · derivative.exercise_date: The option vests 1/48 on each monthly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date.

SEC source: 0001628280-25-039734 · wk-form4_1754960465.xml · nonDerivative · entry 1

Verghese Vikram · CIK 0002079946 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,867

F1 · shares: Represents restricted stock units ("RSUs"), with a vesting commencement date of August 7, 2025 (the "Vesting Commencement Date"). 1/16th of the RSUs vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date.

SEC source: 0001628280-25-039730 · wk-form4_1754960439.xml · derivative · entry 23

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,420

Underlying: Common Stock · 47,420 shares

Expires 2035-08-07

F7 · derivative.exercise_date: The option will vest in full on the earlier of Heartflow's annual meeting of shareholders in 2026 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001628280-25-039738 · wk-form4_1754960493.xml · derivative · entry 1

Cullivan Julie A · CIK 0001713207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,710

Underlying: Common Stock · 23,710 shares

Expires 2035-08-07

F1 · derivative.exercise_date: The option will vest in full on the earlier of Heartflow, Inc.'s annual meeting of shareholders in 2026 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001628280-25-039736 · wk-form4_1754960479.xml · derivative · entry 1

Riley Wayne Joseph · CIK 0001432895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,710

Underlying: Common Stock · 23,710 shares

Expires 2035-08-07

F1 · derivative.exercise_date: The option will vest in full on the earlier of Heartflow, Inc.'s annual meeting of shareholders in 2026 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001628280-25-039737 · wk-form4_1754960486.xml · derivative · entry 2

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,710

Underlying: Common Stock · 23,710 shares

Expires 2035-08-07

F3 · derivative.exercise_date: The option will vest in full on the earlier of Heartflow's annual meeting of shareholders in 2026 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001628280-25-039735 · wk-form4_1754960473.xml · derivative · entry 2

Farquhar John C.M. · CIK 0001900415 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 314,603

Underlying: Common Stock · 314,603 shares

Expires 2035-08-07

F2 · derivative.exercise_date: The option vests 1/48 on each monthly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date.